Surface Oncology, Inc. SURF
1.07 0.00 (+0.00%)
At closeSep 7, 2023, 4:00 PM EDT
1.01 Day range 1.09
0.555 52-week range 1.43
Analyst view
Consensus: hold
Hold
Price target (mean) 2.38 +122.4% upside
Now 1.07
- Target (low)
- 1.00
- Target (mean)
- 2.38
- Target (high)
- 5.00
Ratings (0m) 2 1 buy · 1 hold · 0 sell
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 2
- 1 month ago 5
- 2 months ago 6
- 3 months ago 2
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.34 | -0.35 – -0.33 | -0.46 | +26.1% | 0 | 0.0% | 5 |
| Next quarter | -0.35 | -0.37 – -0.34 | -0.39 | +10.3% | 0 | 0.0% | 5 |
| Current year | -1.29 | -1.42 – -1.11 | -1.14 | -13.2% | 3.75M | -87.5% | 5 |
| Next year | -1.18 | -1.54 – -0.95 | -1.29 | +8.5% | 0 | 0.0% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 23, 2023 | Baird | Maintained | Outperform | Outperform |
| Jun 20, 2023 | Wedbush | Downgrade | Outperform | Neutral |
| Jun 20, 2023 | Baird | Downgrade | Outperform | Neutral |
| Jun 20, 2023 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| May 5, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 10, 2023 | Wedbush | Reiterated | — | Outperform |
| Mar 10, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Nov 3, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Aug 8, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| May 18, 2021 | BTIG | Initiated | — | Buy |
| Sep 4, 2020 | HC Wainwright & Co. | Initiated | — | Buy |
| Aug 28, 2020 | Wedbush | Initiated | — | Outperform |
| Sep 19, 2018 | Baird | Initiated | — | Outperform |
| May 14, 2018 | Goldman Sachs | Initiated | — | Neutral |
| May 14, 2018 | Cowen & Co. | Initiated | — | Outperform |
| May 14, 2018 | Evercore ISI Group | Initiated | — | Outperform |